Department of Endocrinology, Department of Molecular Medicine and Surgery, Metabolism and Diabetology, Karolinska University Hospital, 171 76 Stockholm, Sweden
Search for other papers by Charlotte Höybye in
Google Scholar
PubMed
Search for other papers by Erik Wahlström in
Google Scholar
PubMed
Search for other papers by Petra Tollet-Egnell in
Google Scholar
PubMed
Search for other papers by Gunnar Norstedt in
Google Scholar
PubMed
with healthy controls, and changes in metabolic profile during GH treatment and after discontinuation of GH replacement was observed. The aims of this study were to detect the levels of serum metabolome in GHD patients and healthy subjects and to find
Search for other papers by A C Paepegaey in
Google Scholar
PubMed
Search for other papers by M Coupaye in
Google Scholar
PubMed
Search for other papers by A Jaziri in
Google Scholar
PubMed
Search for other papers by F Ménesguen in
Google Scholar
PubMed
Search for other papers by B Dubern in
Google Scholar
PubMed
Search for other papers by M Polak in
Google Scholar
PubMed
Search for other papers by J M Oppert in
Google Scholar
PubMed
Search for other papers by M Tauber in
Google Scholar
PubMed
Search for other papers by G Pinto in
Google Scholar
PubMed
INSERM, UMRS 1166, Nutriomic Group 6, Paris, France
Sorbonne Université, UMRS1166, Paris, France
Search for other papers by C Poitou in
Google Scholar
PubMed
, sex-hormone treatment in adulthood, GH treatment during childhood and/or in adulthood. The two-sided significance level was fixed at 5%. Statistical analyses were performed using JMP statistic software (SAS Institute Inc. Cary, NC, USA
Search for other papers by Ekaterina Koledova in
Google Scholar
PubMed
Search for other papers by George Stoyanov in
Google Scholar
PubMed
Search for other papers by Leroy Ovbude in
Google Scholar
PubMed
Search for other papers by Peter S W Davies in
Google Scholar
PubMed
catch-up growth ( 1 , 2 , 3 ). The aim of GH treatment is to initiate catch-up growth and improve adult height and metabolic parameters, which requires long-term commitment from the patient and/or carer for regular injections. The length of continuous
Search for other papers by Lukas Plachy in
Google Scholar
PubMed
Search for other papers by Lenka Petruzelkova in
Google Scholar
PubMed
Search for other papers by Petra Dusatkova in
Google Scholar
PubMed
Search for other papers by Klara Maratova in
Google Scholar
PubMed
Search for other papers by Dana Zemkova in
Google Scholar
PubMed
Search for other papers by Lenka Elblova in
Google Scholar
PubMed
Search for other papers by Vit Neuman in
Google Scholar
PubMed
Search for other papers by Stanislava Kolouskova in
Google Scholar
PubMed
Search for other papers by Barbora Obermannova in
Google Scholar
PubMed
Search for other papers by Marta Snajderova in
Google Scholar
PubMed
Search for other papers by Zdenek Sumnik in
Google Scholar
PubMed
Search for other papers by Jan Lebl in
Google Scholar
PubMed
Search for other papers by Stepanka Pruhova in
Google Scholar
PubMed
between children with monogenic FSS compared to those with no monogenic FSS etiology elucidated. Monogenic FSS No monogenic etiology elucidated P -value Height before GH treatment (SD) −3.1 (−3.6 to −2.7) −3.0 (−3.5 to −2
Search for other papers by Imane Benabbad in
Google Scholar
PubMed
Search for other papers by Myriam Rosilio in
Google Scholar
PubMed
Search for other papers by Maité Tauber in
Google Scholar
PubMed
Search for other papers by Emmanuel Paris in
Google Scholar
PubMed
Search for other papers by Anne Paulsen in
Google Scholar
PubMed
Search for other papers by Lovisa Berggren in
Google Scholar
PubMed
Search for other papers by Hiren Patel in
Google Scholar
PubMed
Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Universitaire Robert-Debré, Department of Pediatric Endocrinology and Diabetology, and Centre de Référence des Maladies Endocriniennes Rares de la Croissance, Paris, France
Search for other papers by Jean-Claude Carel in
Google Scholar
PubMed
Search for other papers by the Phoenix Study Group in
Google Scholar
PubMed
cause short stature have been excluded ( 1 ). Various studies have shown that growth hormone (GH) treatment of children with ISS can increase their growth velocity and, to a lesser extent, adult height ( 1 , 2 , 3 , 4 , 5 , 6 ). The effect on height
Search for other papers by Régis Coutant in
Google Scholar
PubMed
Pediatric team of the Clinical Investigation Center 9302/INSERM, Hospital of Children, Toulouse, France
Institut Toulousain des Maladies Infectieuses et Inflammatoires (Infinity), INSERM UMR1291 - CNRS UMR5051 - Université Toulouse III, Toulouse, France
Search for other papers by Maithé Tauber in
Google Scholar
PubMed
Search for other papers by Béatrice Demaret in
Google Scholar
PubMed
Search for other papers by Robin Henocque in
Google Scholar
PubMed
Search for other papers by Yves Brault in
Google Scholar
PubMed
Search for other papers by François Montestruc in
Google Scholar
PubMed
Patient-Reported Outcomes Unit (PROQOL), UMR 1123, University Paris Cité, INSERM, Paris, France
Search for other papers by Olivier Chassany in
Google Scholar
PubMed
Search for other papers by Michel Polak in
Google Scholar
PubMed
Search for other papers by the QOLITHOR Study Group in
Google Scholar
PubMed
ρ = 0 ( α = 0.05 two-sided) for the level of the overall life interference total score according to the GH treatment duration (analyzed as a continuous variable) had 90% power to detect a correlation coefficient ρ of at least 0.25. The
Search for other papers by Thomas Reinehr in
Google Scholar
PubMed
Search for other papers by Martin Carlsson in
Google Scholar
PubMed
Search for other papers by Dionisios Chrysis in
Google Scholar
PubMed
Search for other papers by Cecilia Camacho-Hübner in
Google Scholar
PubMed
of GH treatment and adult height in children with GHD is lower compared to target height even though the children were treated adequately with growth hormone (GH) ( 13 ), we hypothesize that adult height prediction based on bone age will overestimate
Search for other papers by Gudmundur Johannsson in
Google Scholar
PubMed
Search for other papers by Martin Bidlingmaier in
Google Scholar
PubMed
Search for other papers by Beverly M K Biller in
Google Scholar
PubMed
Search for other papers by Margaret Boguszewski in
Google Scholar
PubMed
Search for other papers by Felipe F Casanueva in
Google Scholar
PubMed
Search for other papers by Philippe Chanson in
Google Scholar
PubMed
Search for other papers by Peter E Clayton in
Google Scholar
PubMed
Search for other papers by Catherine S Choong in
Google Scholar
PubMed
Search for other papers by David Clemmons in
Google Scholar
PubMed
Search for other papers by Mehul Dattani in
Google Scholar
PubMed
Search for other papers by Jan Frystyk in
Google Scholar
PubMed
Search for other papers by Ken Ho in
Google Scholar
PubMed
Search for other papers by Andrew R Hoffman in
Google Scholar
PubMed
Search for other papers by Reiko Horikawa in
Google Scholar
PubMed
Search for other papers by Anders Juul in
Google Scholar
PubMed
Search for other papers by John J Kopchick in
Google Scholar
PubMed
Search for other papers by Xiaoping Luo in
Google Scholar
PubMed
Search for other papers by Sebastian Neggers in
Google Scholar
PubMed
Search for other papers by Irene Netchine in
Google Scholar
PubMed
Search for other papers by Daniel S Olsson in
Google Scholar
PubMed
Search for other papers by Sally Radovick in
Google Scholar
PubMed
Search for other papers by Ron Rosenfeld in
Google Scholar
PubMed
Search for other papers by Richard J Ross in
Google Scholar
PubMed
Search for other papers by Katharina Schilbach in
Google Scholar
PubMed
Search for other papers by Paulo Solberg in
Google Scholar
PubMed
Search for other papers by Christian Strasburger in
Google Scholar
PubMed
Search for other papers by Peter Trainer in
Google Scholar
PubMed
Search for other papers by Kevin C J Yuen in
Google Scholar
PubMed
Search for other papers by Kerstin Wickstrom in
Google Scholar
PubMed
Search for other papers by Jens O L Jorgensen in
Google Scholar
PubMed
Search for other papers by on behalf of the Growth Hormone Research Society in
Google Scholar
PubMed
endpoint in trials involving GH treatment and medical treatment of acromegaly, neither GH nor IGF-I has been subject to a structured evaluation as biomarkers, nor do we have a comprehensive definition of clinical endpoints for the treatment of GH
Search for other papers by Alicia Romano in
Google Scholar
PubMed
Search for other papers by Juan Pablo Kaski in
Google Scholar
PubMed
Search for other papers by Jovanna Dahlgren in
Google Scholar
PubMed
Search for other papers by Nicky Kelepouris in
Google Scholar
PubMed
Search for other papers by Alberto Pietropoli in
Google Scholar
PubMed
Search for other papers by Tilman R Rohrer in
Google Scholar
PubMed
Search for other papers by Michel Polak in
Google Scholar
PubMed
stenosis (PVS; prevalence 50–60%), hypertrophic cardiomyopathy (HCM; 20%) and atrial septal defects (6–10%) ( 1 ). Growth hormone (GH) treatment in patients with NS improves height velocity, height standard deviation score (SDS) and adult height, with a
Department of Molecular Medicine and Surgery, Karolinska Institute, Stockholm, Sweden
Search for other papers by Charlotte Höybye in
Google Scholar
PubMed
Search for other papers by Laia Faseh in
Google Scholar
PubMed
Department of Medicine, Karlstad Hospital, Karlstad, Sweden
Search for other papers by Christos Himonakos in
Google Scholar
PubMed
Search for other papers by Tomasz Pielak in
Google Scholar
PubMed
Search for other papers by Jesper Eugen-Olsen in
Google Scholar
PubMed
shown that GH treatment improves the above-mentioned risk factors for CVD ( 1 , 2 , 3 , 5 , 6 , 7 , 12 , 13 , 14 ), but it is currently unknown if GHD and long-term GHD treatment influences the level of low-grade inflammation. Urokinase